TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21592994

Group type: EXPERIMENTAL
Intervention: Pre-ART and 1-month C-reactive protein (CRP) levels
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pre-ART and 1-month D-dimer levels
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pre-ART and 1-month interleukin 6 (IL-6) levels
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pre-ART hyaluronic acid (HA) levels
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Baseline CRP levels above cohort median (>2.1 mg/L)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Baseline HA levels above cohort median (>50.0 ng/mL)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Patients with immune reconstitution inflammatory syndrome (IRIS) events
Number of subjects: 189
Study: 19429065

Group type: EXPERIMENTAL
Intervention: BT-11
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16903879

Group type: EXPERIMENTAL
Intervention: Oral artesunate‐mefloquine (AM)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Oral dihydroartemisinin‐piperaquine (DP)
Number of subjects: 220
Study: 15007110

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin daily (intensive therapy)
Number of subjects: 4162

Group type: COMPARATOR
Intervention: 40 mg of pravastatin daily (standard therapy)
Number of subjects: 4162
Study: 11729943

Group type: EXPERIMENTAL
Intervention: Live graded exposure (LGE)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Computer-aided vicarious exposure (CAVE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 28
Study: 9868115

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine and western medicine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Regular medicine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Peritoneal cavity administration
Number of subjects: 88
Study: 7869017

Group type: EXPERIMENTAL
Intervention: Radiation treatment after October 1985
Number of subjects: 193

Group type: COMPARATOR
Intervention: Definitive radiotherapy and fat soluble chemotherapy (not utilized in earlier cases)
Number of subjects: 193
Study: 2904757

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 to 16 mg once daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Enalapril (10 to 40 mg once daily)
Number of subjects: 67
Study: 30803899

Group type: EXPERIMENTAL
Intervention: Z‐CFPD
Number of subjects: 21

Group type: COMPARATOR
Intervention: MC‐CFPD
Number of subjects: 21
Study: 27228002

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL) ovarian drilling
Number of subjects: 246
Study: 25460267

Group type: EXPERIMENTAL
Intervention: Public speaking condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (silent reading) condition
Number of subjects: 0
Study: 23356862

Group type: EXPERIMENTAL
Intervention: Healthy Caregivers‐Healthy Children (HC2) intervention
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Attention control safety curriculum (Control)
Number of subjects: 1105
Study: 21716297

Group type: EXPERIMENTAL
Intervention: 20 mg simvastatin daily for 6 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 18642634

Group type: EXPERIMENTAL
Intervention: In-hospital neurorehabilitation (4.9% of hospitalized TBI)
Number of subjects: 6783

Group type: EXPERIMENTAL
Intervention: In-hospital neurorehabilitation
Number of subjects: 6783

Group type: EXPERIMENTAL
Intervention: TBI severity, patient's age, concomitant organ lesions, and complications
Number of subjects: 6783
Study: 17134628

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 111

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 111
Study: 13130200

Group type: EXPERIMENTAL
Intervention: Fixed-dose fluticasone-salmeterol combination (FP/S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled corticosteroids and long-acting B2-agonists given separately (TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of FP/S and TC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolerance
Number of subjects: 0
Study: 11702613

Group type: EXPERIMENTAL
Intervention: Topical retinol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9176691

Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (PHM) 7 gm, twice‐daily added to continuous feeding
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (PHM) given as a bolus with intermittent feeding
Number of subjects: 60

Group type: COMPARATOR
Intervention: No PHM for 7 days after initiation of enteral feeding
Number of subjects: 60
Study: 1382251

Group type: EXPERIMENTAL
Intervention: High dose Aprotinin (two subgroups with different doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3891455

Group type: EXPERIMENTAL
Intervention: Oxazepam Expidet 30 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oxazepam Expidet
Number of subjects: 72
Study: 30265572

Group type: EXPERIMENTAL
Intervention: School-based inhibitory control training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 19
Study: 30187935

Group type: EXPERIMENTAL
Intervention: Ticagrelor 0.125 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ticagrelor 0.563 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ticagrelor 0.75 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ticagrelor 2.25 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ticagrelor (0.125, 0.563, or 0.75 mg/kg bid)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 61
Study: 27330010

Group type: EXPERIMENTAL
Intervention: Transcatheter interatrial shunt device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25164709

Group type: EXPERIMENTAL
Intervention: Dosing nomogram (65 patients)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard care (66 patients)
Number of subjects: 131
Study: 22583459

Group type: EXPERIMENTAL
Intervention: HIT-6 algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSQ algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIT-6 and MSQ algorithms
Number of subjects: 0
Study: 20191258

Group type: EXPERIMENTAL
Intervention: Nutritional formulation (NF) consisting of folic acid, B12, Vitamin E, S‐adenosylmethionine, N‐acetyl cysteine, and Acetyl‐L‐carnitine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional formulation (NF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18400837

Group type: EXPERIMENTAL
Intervention: High-intensity weight-bearing exercises
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 281
Study: 15800716

Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy with mitomycin C and bleomycin
Number of subjects: 95
Study: 12584669

Group type: EXPERIMENTAL
Intervention: Candesartan treatment
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3400
Study: 11560727

Group type: EXPERIMENTAL
Intervention: Paediatric hospital at home service (HAH)
Number of subjects: 40
Study: 9397080

Group type: COMPARATOR
Intervention: Indomethacin 50 mg twice daily
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ketoprofen 200 mg once daily
Number of subjects: 113
Study: 8215148

Group type: EXPERIMENTAL
Intervention: No touch technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hand in technique
Number of subjects: 100
Study: 3826293

Group type: EXPERIMENTAL
Intervention: Slow vergence training rate (0.75 delta/s)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fast vergence training rate (5.00 delta/s)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 18
Study: 30157924

Group type: EXPERIMENTAL
Intervention: 32 mg buprenorphine
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 64 mg buprenorphine
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 96 mg buprenorphine
Number of subjects: 51
Study: 28653377

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 226

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Both HES and Ringer's acetate
Number of subjects: 226
Study: 26362831

Group type: EXPERIMENTAL
Intervention: Nebivolol (beta-blocker)
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Valsartan (angiotensin receptor blocker)
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Combination treatment (20 mg nebivolol/320 mg valsartan)
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 805
Study: 23232993

Group type: EXPERIMENTAL
Intervention: Single‐incision laparoscopic surgery (SILS) cholecystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 40
Study: 21709162

Group type: EXPERIMENTAL
Intervention: WIISARD (electronic pathway)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (paper-based pathway)
Number of subjects: 100
Study: 17604930

Group type: EXPERIMENTAL
Intervention: Low-attenuation barium sulphate suspension
Number of subjects: 90

Group type: COMPARATOR
Intervention: High-attenuation barium sulphate preparation
Number of subjects: 90
Study: 16451158

Group type: EXPERIMENTAL
Intervention: HES (130/0.4)
Number of subjects: 42

Group type: COMPARATOR
Intervention: FFP (10 ml/kg)
Number of subjects: 42
Study: 12721160

Group type: EXPERIMENTAL
Intervention: FSH/IUI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 11110875

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9264047

Group type: EXPERIMENTAL
Intervention: Sinemet or Sinemet-CR (carbidopa-levodopa association) taken 0.5, 1, 2, 4, 8, 12 hours before collection
Number of subjects: 70
Study: 1437922

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (60 mg infusion over 2 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (infusions over 4, 8, or 24 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (various infusion rates)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (short infusions)
Number of subjects: 0
Study: 29067834

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 72
Study: 28819922

Group type: EXPERIMENTAL
Intervention: Therapist-delivered cognitive behavior therapy/motivational interviewing (CBT/MI)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Computer-delivered CBT/MI with brief therapist assistance (SHADE CBT/MI)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Supportive counseling (PCT)
Number of subjects: 274
Study: 25908605

Group type: EXPERIMENTAL
Intervention: Oral S-1 plus cisplatin (80 mg/m2/day on days 1-21 plus cisplatin 60 mg/m2 on day 8 every 4-5 weeks)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin (60 mg/m2 on day 1 plus cisplatin 80 mg/m2 on day 1 every 3-4 weeks)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin
Number of subjects: 608
Study: 23778853

Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21191095

Group type: EXPERIMENTAL
Intervention: Tangible reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No reward
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 0
Study: 18447222

Group type: EXPERIMENTAL
Intervention: Three needling method (acupuncture at Huantiao (GB 30), Yanglingquan (GB 34), Shenmai (BL 62), with needling at shallow, middle, and deep layers, followed by massage at the Foot‐Taiyang Channel and Foot‐Shaoyang Channel)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine needling (acupuncture at Huantiao (GB 30), Juliao (GB 29), Chengfu (BL 36), Yanglingquan (GB 34), followed by massage)
Number of subjects: 82
Study: 17345837

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: levocetirizine 5 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: fexofenadine 120 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: fexofenadine 180 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 14570783

Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia using propofol
Number of subjects: 305

Group type: COMPARATOR
Intervention: Inhalation anaesthesia using sevoflurane
Number of subjects: 305
Study: 10781481

Group type: EXPERIMENTAL
Intervention: Chloroprocaine (4.5 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study: 8635674

Group type: EXPERIMENTAL
Intervention: 100 mmol/day sodium supplement (group 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo (group 1)
Number of subjects: 16
Study: 1425867

Group type: EXPERIMENTAL
Intervention: Theophylline (Th) 450-900 mg in the evening
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Theophylline (Th)
Number of subjects: 7
Study: 2580168

Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol plus diuretic
Number of subjects: 97

Group type: COMPARATOR
Intervention: Captopril plus diuretic
Number of subjects: 97
Study: 29931657

Group type: EXPERIMENTAL
Intervention: Vitamin D (4000 IU)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 26351927

Group type: EXPERIMENTAL
Intervention: Enteral melatonin (6 mg total: 3 mg loading dose at 9 pm + six 0.5 mg doses hourly)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (administered using a similar regimen to melatonin)
Number of subjects: 13
Study: 24732894

Group type: EXPERIMENTAL
Intervention: Argatroban (10 mg intravenous twice daily for 2 days before and 3 days after stenting)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 114
Study: 24294573

Group type: EXPERIMENTAL
Intervention: 2% Lidocaine with one in 200,000 adrenaline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with one in 200,000 adrenaline in distilled water
Number of subjects: 30
Study: 20938358

Group type: EXPERIMENTAL
Intervention: LG‐SM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SM‐LG
Number of subjects: 0

Group type: COMPARATOR
Intervention: CG
Number of subjects: 0
Study: 16411223

Group type: EXPERIMENTAL
Intervention: Irinotecan followed by cisplatin (I-P)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisplatin followed by irinotecan (P-I)
Number of subjects: 80
Study: 15314593

Group type: EXPERIMENTAL
Intervention: Parent-administered visual acuity testing using the EVA (Group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Full ATS protocol (Group B)
Number of subjects: 108
Study: 11269893

Group type: EXPERIMENTAL
Intervention: Miglitol (25 to 100 mg trice daily for 24 weeks)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 154
Study: 9017770

Group type: EXPERIMENTAL
Intervention: Enalapril-diltiazem ER (dosage titrated to response, maximum of enalapril 10 mg-diltiazem ER 360 mg/day)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Enalapril 5 mg-diltiazem ER 120 mg once/day (titrated to response)
Number of subjects: 265
Study: 8300456

Group type: EXPERIMENTAL
Intervention: Hydralazine-ISDN
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 3520626

Group type: EXPERIMENTAL
Intervention: House dust mite avoidance (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study: 30681971

Group type: EXPERIMENTAL
Intervention: Melissa officinalis L. based product (MO), 500 mg capsules, 2 capsules daily for 3 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 37
Study: 28659346

Group type: EXPERIMENTAL
Intervention: Weight-loss diets varying in macronutrient content
Number of subjects: 692

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 692
Study: 25845978

Group type: COMPARATOR
Intervention: High-pressure, low-volume nasal saline (HPLVNS) irrigation
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Low-pressure, high-volume nasal saline (LPHVNS) irrigation with fluticasone propionate (FP)
Number of subjects: 73
Study: 24163425

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl during exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham injection (control) during exercise
Number of subjects: 9
Study: 21114892

Group type: EXPERIMENTAL
Intervention: Medium-GI carbohydrates
Number of subjects: 25943

Group type: COMPARATOR
Intervention: High-GI carbohydrates
Number of subjects: 25943

Group type: COMPARATOR
Intervention: Low-GI carbohydrates
Number of subjects: 25943
Study: 20104985

Group type: EXPERIMENTAL
Intervention: Self-rating depression scale (SDS)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Self-rating anxiety scale (SAS)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Combined anxiety and depression
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Depression with anxiety
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Depression with sub-anxiety
Number of subjects: 560
Study: 17760599

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream used daily in conjunction with laser therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo used daily in conjunction with laser therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16344026

Group type: EXPERIMENTAL
Intervention: Comprehensive neurorehabilitation program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional rehabilitation (Control)
Number of subjects: 19
Study: 11865364

Group type: COMPARATOR
Intervention: Glucose group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fat group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study: 10510923

Group type: EXPERIMENTAL
Intervention: Functional continuous magnetic stimulation (15-minute session at 20 Hz, 1-minute-on/30-second-off cycles)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham group (no stimulation)
Number of subjects: 10
Study: 7781653

Group type: EXPERIMENTAL
Intervention: 1.0 g ascorbic acid (AA) and 0.2 g pantothenic acid (PA) supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 49
Study: 2396603

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 386677

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 137

Group type: COMPARATOR
Intervention: Oxytetracycline
Number of subjects: 137
Study: 31010241

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 plus vitamin B6 (ZR)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 23
Study: 27412664

Group type: EXPERIMENTAL
Intervention: Usual routine treatment with exercise training (n=44)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual routine treatment without training (n=20)
Number of subjects: 64
Study: 26099752

Group type: EXPERIMENTAL
Intervention: Epidural injection of 80 mg triamcinolone and 8 ml bupivacaine 0.25%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural injection of 8 ml bupivacaine 0.25%
Number of subjects: 0
Study: 23747802

Group type: EXPERIMENTAL
Intervention: Combined inpatient physical training (aerobic + strength) for the duration of neoadjuvant chemotherapy, 3 weekly 60-70 min exercise sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined inpatient physical training (aerobic + strength)
Number of subjects: 60
Study: 21238614

Group type: EXPERIMENTAL
Intervention: Culturally specific intervention using bouts of physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18575980

Group type: EXPERIMENTAL
Intervention: Quality-of-life adjusted failure time estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Competing censoring mechanisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment for recorded prognostic factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalization from single to many censoring processes
Number of subjects: 0
Study: 17077058

Group type: EXPERIMENTAL
Intervention: High protein high fibre snack bar
Number of subjects: 23

Group type: COMPARATOR
Intervention: High fat high sugar snack bar
Number of subjects: 23
Study: 15577047

Group type: EXPERIMENTAL
Intervention: Raroxifene treatment
Number of subjects: 0
Study: 11439379

Group type: EXPERIMENTAL
Intervention: Conventional steroid treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Submaximal intermittent fatigue protocol (0.6 duty cycle)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Maximal and submaximal relative integrated electromyogram (IEMG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9